Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Xeris Biopharma's operating margin for the twelve months ending Jun 30, 2026 was 10.9%. For fiscal 2025 it was 8.5%, against -16.6% the year before. The highest annual figure on record is 8.5% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.5% | +25.1 |
| FY2024 | Dec 31, 2024 | -16.6% | +10.3 |
| FY2023 | Dec 31, 2023 | -26.8% | +47.5 |
| FY2022 | Dec 31, 2022 | -74.3% | +157.9 |
| FY2021 | Dec 31, 2021 | -232.2% | +176.6 |
| FY2020 | Dec 31, 2020 | -408.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 5.6% | −0.6 |
| Q1 FY2026 | Mar 31, 2026 | 9.5% | +14.7 |
| Q4 FY2025 | Dec 31, 2025 | 19.5% | +16.8 |
| Q3 FY2025 | Sep 30, 2025 | 9.0% | +32.8 |
| Q2 FY2025 | Jun 30, 2025 | 6.3% | +23.3 |
| Q1 FY2025 | Mar 31, 2025 | -5.1% | +29.9 |
| Q4 FY2024 | Dec 31, 2024 | 2.8% | +25.0 |
| Q3 FY2024 | Sep 30, 2024 | -23.8% | −13.6 |
| Q2 FY2024 | Jun 30, 2024 | -17.0% | +25.0 |
| Q1 FY2024 | Mar 31, 2024 | -35.1% | +4.9 |
| Q4 FY2023 | Dec 31, 2023 | -22.2% | +23.6 |
| Q3 FY2023 | Sep 30, 2023 | -10.2% | +53.0 |
| Q2 FY2023 | Jun 30, 2023 | -42.0% | +32.7 |
| Q1 FY2023 | Mar 31, 2023 | -40.0% | +91.7 |
| Q4 FY2022 | Dec 31, 2022 | -45.8% | +179.5 |
| Q3 FY2022 | Sep 30, 2022 | -63.2% | +157.1 |
| Q2 FY2022 | Jun 30, 2022 | -74.7% | +214.8 |
| Q1 FY2022 | Mar 31, 2022 | -131.7% | +72.6 |
| Q4 FY2021 | Dec 31, 2021 | -225.3% | +37.2 |
| Q3 FY2021 | Sep 30, 2021 | -220.2% | −74.1 |
| Q2 FY2021 | Jun 30, 2021 | -289.5% | – |
| Q1 FY2021 | Mar 31, 2021 | -204.3% | – |
| Q4 FY2020 | Dec 31, 2020 | -262.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -146.2% | – |
See a number that looks wrong?